Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use.
Insulin pens offer significant benefits over vial and syringe injections for patients with diabetes who require insulin therapy. Insulin pens are more discreet, easier for patients to hold and inject, and provide better dosing accuracy than vial and syringe injections. The Humalog(®) KwikPen™ (prefilled insulin lispro [Humalog] pen, Eli Lilly and Company, Indianapolis, IN, USA) is a prefilled insulin pen highly rated by patients for ease of use in injections, and has been preferred by patients to both a comparable insulin pen and to vial and syringe injections in comparator studies. Together with an engineering study demonstrating smoother injections and reduced dosing error versus a comparator pen, recent evidence demonstrates the Humalog KwikPen device is an accurate, easy-to-use, patient-preferred insulin pen.
DGD Research, 5107 Medical Drive, San Antonio, TX 78229, USA.
Sherwyn L
SL
Schwartz
Debra A
DA
Ignaut
Jennifer N
JN
Bodie
D003920:Diabetes Mellitus / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000295:instrumentation; D004867:Equipment Design; D019544:Equipment Failure Analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D007328:Insulin / Q000008:administration & dosage*; D010349:Patient Compliance; D017060:Patient Satisfaction; D012646:Self Administration / Q000295:instrumentation*; D013594:Syringes
D007004:Hypoglycemic Agents; D007328:Insulin